<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In the U.S., ∼ 21 × 10(6) individuals have type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and twice as many have <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> (IGT) </plain></SENT>
<SENT sid="1" pm="."><plain>Approximately 40-50% of individuals with IGT will progress to type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> over their lifetime </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, treatment of high-risk individuals with IGT to prevent type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> has important medical, economic, social, and human implications </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0001824'>Weight loss</z:hpo>, although effective in reducing the conversion of IGT to type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, is difficult to achieve and maintain </plain></SENT>
<SENT sid="4" pm="."><plain>Moreover, 40-50% of IGT subjects progress to type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> despite successful weight reduction </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, pharmacological treatment of IGT with oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agents that improve insulin sensitivity and preserve β-cell function--the characteristic pathophysiological abnormalities present in IGT and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>--uniformly have been shown to prevent progression of IGT to type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>The most consistent results have been observed with the <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> (<z:chebi fb="0" ids="9753">Troglitazone</z:chebi> in the Prevention of <z:mp ids='MP_0002055'>Diabetes</z:mp> [TRIPOD], <z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> in the Prevention of <z:mp ids='MP_0002055'>Diabetes</z:mp> [PIPOD], <z:mp ids='MP_0002055'>Diabetes</z:mp> Reduction Assessment with <z:chebi fb="0" ids="8774">Ramipril</z:chebi> and <z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> Medication [DREAM], and Actos Now for the Prevention of <z:mp ids='MP_0002055'>Diabetes</z:mp> [ACT NOW]), with a 50-70% reduction in IGT conversion to <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> in the U.S </plain></SENT>
<SENT sid="8" pm="."><plain><z:mp ids='MP_0002055'>Diabetes</z:mp> Prevention Program (DPP) reduced the development of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> by 31% and has been recommended by the American <z:mp ids='MP_0002055'>Diabetes</z:mp> Association (<z:chebi fb="36" ids="39048">ADA</z:chebi>) for treating high-risk individuals with IGT </plain></SENT>
<SENT sid="9" pm="."><plain>The glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 analogs, which augment insulin secretion, preserve β-cell function, and promote <z:hpo ids='HP_0001824'>weight loss</z:hpo>, also would be expected to be efficacious in preventing the progression of IGT to type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>Because individuals in the upper tertile of IGT are maximally/near-maximally insulin resistant, have lost 70-80% of their β-cell function, and have an ∼ 10% incidence of diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo>, pharmacological intervention, in combination with diet plus exercise, should be instituted </plain></SENT>
</text></document>